10 April 2025 – Icon Cancer Centre and Omico have announced an important collaboration aimed at expanding access to precision oncology and clinical trials for Australian cancer patients. By leveraging Icon’s extensive national network of cancer centres and Omico’s expertise in molecular profiling and targeted therapy trials, this partnership is set to improve access to cancer screening and evolve Australia’s cancer care landscape. 

Increasing access to genomic profiling and research  
This partnership will advance cancer care by making precision oncology more accessible in routine practice. It aims to provide Australians living with challenging cancers access to free comprehensive genomic profiling (CGP), opening the door to life-extending, personalised treatments that may otherwise remain unexplored.

The collaboration will also focus on expanding clinical trial availability across Icon’s national network, ensuring that more patients, including those in non-metropolitan and regional areas, can access advanced therapies and contribute to leading-edge research. It will also improve clinician engagement and support for integrating genomic-guided treatment options into everyday care.

The partnership focuses on Omico’s PrOSPeCT*, Australia’s largest precision oncology initiative. Through PrOSPeCT, 23,000 patients with advanced, incurable or poor prognosis cancers will receive free comprehensive genomic profiling (CGP) to identify potential matches with clinical trials, offering patients access to cutting-edge, personalised treatments. CaSP – The Cancer Screening Program within PrOSPeCT – receives patient referrals, coordinates CGP testing, and delivers a comprehensive report to the referring clinician, including genomic results and potential matches to molecularly guided trials, helping clinicians provide tailored treatment options for their patients.

Evolving targeted treatments
Icon Cancer Centre Medical Oncologist, A/Prof Louise Nott is looking forward to clinical improvements. 

“Every cancer diagnosis is different, and genomic testing is transforming the way we treat cancer and deliver truly personalised care,” said A/Prof Nott. 

“By identifying the unique drivers of a patient’s cancer, we can match them with targeted therapies and clinical trials that can offer improved outcomes. Partnering with Omico is a crucial step in evolving clinician access to genomic-guided treatment and ultimately ensuring patients have better access to innovative treatments.” 

Bringing cutting-edge closer to home
Chief of Science and Strategy at Omico, Prof David Thomas said this will accelerate change.

“Every person affected by cancer deserves access to the latest advances in care and treatment, no matter where they are treated,” said Prof Thomas. 

“Icon’s innovation and expertise in delivering cancer services makes them an ideal partner in our mission to ensure contemporary cancer care is within reach for every patient.”

CEO of Omico, Ian Black echoed this sentiment. 

“Omico and Icon are united by a shared commitment: ensuring that access to precision oncology and clinical trials is not limited by geography,” said Ian.  

“Together, we’re focused on building capacity beyond metropolitan centres so that people in regional and rural communities have the same opportunities for cutting-edge cancer care as those in our cities – equity of access must be the standard for every Australian affected by cancer.”

Meeting unmet needs in cancer care
Icon Cancer Centre CEO, Paul Fenton said this is another example of Icon’s commitment to partnerships in addressing care gaps. 

“This partnership addresses a critical gap in patient access to precision oncology,” said Paul.  

“This marks Omico’s first partnership with a national private cancer care provider, creating a new model for integrating precision oncology trials within community-based cancer care and supporting our mission to deliver the best care possible as close to homes as possible.” 

Future healthcare
With more Icon centres actively participating in Omico-supported trials, the collaboration will strengthen biomarker-led research and contribute valuable real-world data on precision oncology. Ultimately, this initiative lays the foundation for a scalable, sustainable model that integrates precision medicine into routine cancer care, shaping the future of oncology in Australia.

–

About Omico
Omico is changing the way we fight cancer by accelerating access to precision oncology. We are the national, independent, not-for-profit organisation, uniting Australia’s world-class cancer institutes, researchers, clinicians, industry partners, government and patient community like never before. By leveraging a nationwide network of expertise and resources, we are facilitating the delivery of genomic cancer medicine clinical trials to thousands of Australians with advanced and incurable cancers. With fast-tracked molecular and genomic screening, biomarker-led trial set up and patient enrolment from the entire nation, we’re accelerating access to next generation treatments and preventive strategies. Learn more at omico.com.au 

*PrOSPeCT – Precision Oncology Screening Program Enabling Clinical Trials

About Icon Cancer Centre Australia and New Zealand
Icon Cancer Centre is part of Icon Group and are pioneers of private cancer care in Australia with over 35 years’ experience. There are currently 40 cancer centres across Australia and a joint venture in New Zealand with several in development. These centres include a mix of dedicated medical oncology, haematology, and radiation oncology facilities, as well as comprehensive cancer centres that bring all services together under one roof, including research and pharmacy. Over half of Icon’s cancer centres are in outer-metro and regional communities delivering on our mission to bring the best possible care, closer to home.  

Learn more at iconcancercentre.com.au